The first six indications have been included in the National Reimbursement Drug List (NRDL) (2023 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. In October 2024, toripalimab for the treatment o...
June 6, 2019—The United Kingdom Medicines & Healthcare Products Regulatory Agency (UK MHRA) announced that it has issued the agency's recommendations for ongoing use of paclitaxel drug-coated balloons (DCBs) and implantable drug-eluting stents (DESs) in the treatment of patients with peripheral...